Finally, ARID1A mutations status was considered to be highly correlated with the level of tumor infiltrating lymphocytes (TILs) and high expression of immune checkpoints.<h4>Conclusions</h4>Patients with tumors harboring ARID1A mutations may achieve better clinical outcomes from immunotherapy, especially in GC. This evidence concerns the gene ARID1A and gastric cancer.